Join
Live feed
·
PRReleasevia Quantisnow
Kymera Therapeutics Inc. logo

Kymera Therapeutics Presents Positive Data Demonstrating Robust IRAK4 Degradation and First Proof-of-Biology with Inhibition of Cytokine Induction from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers

ByQuantisnow·Wall Street's wire, on your screen.
KYMR· Kymera Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KYMR (Kymera Therapeutics Inc.) and more on Quantisnow.